S&P Futures
4,159.00 +12.25 (+0.30%) Dow Futures
32,851.00 +94.00 (+0.29%) Nasdaq Futures
13,289.00 +60.25 (+0.46%) Russell 2000 Futures
1,927.30 +5.50 (+0.29%) Crude Oil
89.64 +0.63 (+0.71%) Gold
1,793.80 +2.60 (+0.15%)
Avalo Therapeutics, Inc. (AVTX)
Chart Events
Performance Outlook
| Previous Close | 4.0500 |
| Open | 4.1800 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 800 |
| Day's Range | 3.8500 - 4.3100 |
| 52 Week Range | 2.4240 - 38.8800 |
| Volume | |
| Avg. Volume | 50,551 |
| Market Cap | 446.464M |
| Beta (5Y Monthly) | 1.75 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8650 |
| Earnings Date | Mar 07, 2022 - Mar 11, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 43.50 |
- GlobeNewswire
Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates
Transferred anti-IL 18 monoclonal antibody product (AVTX-007) to Apollo Therapeutics in July with the approximate $15 million of upfront payment received in AugustDosed first patient in the Phase 2 PEAK Trial of its anti-LIGHT monoclonal antibody (AVTX-002) for the treatment of non-eosinophilic asthma (NEA)Dosed first patient in the Pivotal LADDER Trial of AVTX-803 for the treatment of Leukocyte Adhesion Deficiency Type II (LAD II)Disclosed cash and cash equivalents of $11 million as of June 30,
- GlobeNewswire
Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II)
Topline Pivotal trial results expected 1H2023WAYNE, Pa. and ROCKVILLE, Md., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), announced the first patient has been dosed in the pivotal LADDER trial (A Phase 3, Randomized, Double-blind, Two-period, Crossover, Withdrawal Study to Assess the Efficacy and Safety of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II (LAD II) ER). AVTX-803 is a therapy developed and studied for the treatment of leukocyte adhesion d
- GlobeNewswire
Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics
Avalo to receive an approximately $15 million upfront payment, up to $74 million in milestone payments.Apollo to lead continued clinical development of AVTX-007, currently in Phase 1b ROCKVILLE, Md. and CAMBRIDGE, United Kingdom, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) and Apollo Therapeutics Group Limited have entered into a worldwide, exclusive license agreement granting rights to Apollo to research, develop, manufacture and commercialize AVTX-007 (camoteskima
